Anar Andani

Anar Andani

Auto-generated profile, based on publicly available information

Anar Andani

GSK, Wavre, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Vaccine
Verified
Journal Article
Open access
AAAnar Andani
Anar Andani
PDPierre van Damme
Pierre van Damme
EBEveline M. Bunge
Eveline M. Bunge
FSFernanda Salgado
Fernanda Salgado
RHRosa C. van Hoorn
Rosa C. van Hoorn
BHBernard Hoet
Bernard Hoet
Hepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries have implemented one-dose UV programs since 2005; the long-term impact of this schedule is not yet known. We conducted a systematic literature search in four electronic databases for data published between January 2000 and July 2019 to assess evidence for one-dose and two-dose UV of children with non-live HAV vaccines and describe their global impact on incidence, mortality, and severity of hepatitis A, vaccine effectiveness, vaccine efficacy, and antibody persistence. Of 3739 records screened, 33 peer-reviewed articles and one conference abstract were included. Rapid declines in incidence of hepatitis A and related outcomes were observed in all age groups post-introduction of UV programs, which persisted for at least 14 years for two-dose and six years for one-dose programs according to respective study durations. Vaccine effectiveness was ≥95% over 3-5 years for two-dose programs. Vaccine efficacy was >98% over 0.1-7.5 years for one-dose vaccination. Antibody persistence in vaccinated individuals was documented for up to 15 years (≥90%) and ten years (≥74%) for two-dose and one-dose schedules, respectively. Experience with two-dose UV of children against HAV is extensive, demonstrating an impact on the incidence of hepatitis A and antibody persistence for at least 15 years in many countries globally. Because evidence is more limited for one-dose UV, we were unable to draw conclusions on immune response persistence beyond ten years or the need for booster doses later in life. Ongoing epidemiological monitoring is essential in countries implementing one-dose UV against HAV. Based on current evidence, two doses of non-live HAV vaccines are needed to ensure long-term protection.

1 September 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
AAAnar Andani
Anar Andani
TETessa M. van Elten
Tessa M. van Elten
EBEveline M. Bunge
Eveline M. Bunge
CMCinzia Marano
Cinzia Marano
FSFernanda Salgado
Fernanda Salgado
KJKathryn H. Jacobsen
Kathryn H. Jacobsen
The World Health Organization recommends vaccination against hepatitis A virus (HAV) for children aged 1 year and older in areas where endemicity has shifted from high to intermediate. There are no...

17 February 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
BSBhaskar Shenoy
Bhaskar Shenoy
AAAnar Andani
Anar Andani
SKShafi Kolhapure
Shafi Kolhapure
AAAshish Agrawal
Ashish Agrawal
JMJaydeep Mazumdar
Jaydeep Mazumdar
In the last two decades, outbreaks due to the foodborne hepatitis A virus (HAV) have been frequently reported in India, with adolescents and adults primarily affected. In India, most food handlers are adolescents and young adults who might be exposed to unsatisfactory environmental conditions and poor water quality. This increases the risk of HAV infection and consequently compounds the risk of HAV transmission from food handlers to susceptible populations. Given the shift in hepatitis A endemicity from high to intermediate levels in India, implementing the vaccination of food handlers has become important as it can also contribute to the elimination of hepatitis A in India. This narrative review makes a case for hepatitis A immunization of food handlers in India considering the growing food industry, evolving food culture, and the substantial burden caused by hepatitis A outbreaks. What is the context? What is new? What is the impact?

24 July 2020 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AAAshish Agrawal
Ashish Agrawal
SKShafi Kolhapure
Shafi Kolhapure
AAAnar Andani
Anar Andani
MOMartin O. C. Ota
Martin O. C. Ota
SBselim badur
selim badur
MMMonjori Mitra
Monjori Mitra
Introduction Hepatitis A virus infection is more severe in adults than children. Although vaccination can protect adults, current childhood programs cover a large population more successfully. Childhood vaccination is, therefore, a solution to protecting adults if it induces lasting immunity. Fifteen-year protection has been demonstrated in children, but longer-term data are only available for adults. We aimed to predict long term persistence of antibody in children beyond 15 years and assess if immunological mechanisms triggered by vaccination support longer-term protection. Methods Long-term clinical studies using hepatitis A (HAV) or A/B vaccines (HAB) containing 720 or 1440 Enzyme-linked immunosorbent assay Units (EU) of hepatitis A virus antigen were identified. Duration of persistence of antibodies and possible protection was determined by descriptively comparing antibody geometric mean concentration (GMC) kinetics, as well as GMC (95% confidence interval) at 15 years post-vaccination across studies. Immunological mechanism studies describing hepatitis A vaccination were identified. Results One study in children 12–15 years (2-dose HAB 720) and four in adults (2-dose HAV 1440 and 3-dose HAB 720) showed comparable GMC kinetics and per year rates of change up to 15 years. At 15 years, the GMC in children [414.7 mEU/ml (336.9; 510.5)] was in the same range as in adults [range 282.6 (217.6; 367.0) to 550.1 (416.0; 727.4)]. Based on these data, mathematical model predictions from adult studies (showing > 85% protected at 50 years) were deemed likely to also apply to children. Studies identified, both humoral and cell-mediated responses are induced following vaccination. Conclusion Based on comparable antibody data in adults and children up to 15 years, similar longer-term antibody persistence is expected in children with 2-dose inactivated hepatitis A 720 containing vaccine at least up to 50 years. Accordingly, improving routine childhood hepatitis A vaccination coverage could protect against more severe disease in adulthood. Plain language summary Trial Registration ClinicalTrials.gov identifiers, NCT00875485, NCT01000324, NCT01037114, NCT00289757, NCT00291876.

25 November 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
BRBhaskar Raju
Bhaskar Raju
AAAnar Andani
Anar Andani
SKShafi Kolhapure
Shafi Kolhapure
AAAshish Agrawal
Ashish Agrawal
The burden of chronic liver disease (CLD) in India is high, particularly among middle-aged men, with nearly 220,000 deaths due to cirrhosis in 2017. CLD increases the risk of infection, severe disease (e.g. hepatitis A virus or HAV superinfection, acute-on-chronic liver failure, fulminant hepatic failure), and mortality. Hence, various countries recommend HAV vaccination for CLD patients. While historic Indian studies showed high seroprevalences of protective HAV antibodies among Indian adults with CLD, the most recent ones found that nearly 7% of CLD patients were susceptible to HAV infection. Studies in healthy individuals have shown that HAV infection in childhood is decreasing in India, resulting in an increasing population of adults susceptible to HAV infection. As patients with CLD are at increased risk of severe HAV infection, now may be the time to recommend HAV vaccination among people with CLD in India. What is the context? What is new? What is the impact?

23 October 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AAAnar Andani
Anar Andani
VAVictoria Abbing-Karahagopian
Victoria Abbing-Karahagopian
JKJustina Kavaliauskaite
Justina Kavaliauskaite
TSThierry Oliver Schaffner
Thierry Oliver Schaffner
WSWoo-Yun Sohn
Woo-Yun Sohn
MTMuhamed-Kheir Taha
Muhamed-Kheir Taha
Invasive meningococcal disease (IMD) is uncommon but serious; the case fatality rate is 8-15% and up to 20-40% of survivors experience disabling sequelae, with a substantial socioeconomic impact. Although incidence is highest in infants and young children (aged ≤4 y), a second epidemiologic peak occurs in adolescents and young adults (aged 15-24 y), who are the main carriers of Neisseria meningitidis. We reviewed the burden of IMD in adolescents and young adults in Europe and select geographies including Australia, New Zealand, and Brazil. Globally, there are differing, often suboptimal, vaccination policies with variable vaccination coverage for IMD prevention caused by the major serogroups (A, B, C, W, and Y). The increased risk in adolescents and young adults may relate to their social behaviors. They are difficult to reach due to a reduced incidence of chronic diseases, age-related perceptions of not being at risk, in addition to reliance on technology-based rapid health information searches rather than healthcare professional - based consultations. Absence of standard and comprehensive vaccination programs for the prevention of IMD in adolescents and young adults presents a clear unmet medical need. Existing vaccines against IMD in adolescents are underutilized compared with vaccines against diseases with better awareness and reimbursement schemes. Increasing access to vaccines against IMD, together with innovative strategies such as awareness campaigns and the use of artificial intelligence, as well as practical strategies, such as in-pharmacy vaccination, will be needed to increase the prevention of IMD in adolescents and young adults.